The U.S. health agency extended the review period for the expanded use of AbbVie Inc.’s psoriasis drug Skyrizi by three months, citing the need for more time to review additional data submitted by the company.
The U.S. Food and Drug Administration was reviewing the application for the use of Skyrizi in patients aged 16 years of age or older with moderate to severe Crohn’s disease, a type of inflammatory bowel disease.